Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$3.19 USD
+0.01 (0.31%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
Price, Consensus and EPS Surprise
ABOS 3.19 +0.01(0.31%)
Will ABOS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABOS
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
ABOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Other News for ABOS
These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Acumen presents first clinical, biomarker data for ACU193
Acumen Pharmaceuticals partners with Lonza to advance sabirnetug for the treatment of Alzheimer’s
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease